(HealthDay News) — An open-label, phase 2 trial showed acceptable toxicity and survival rates for the use of proton radiotherapy in children with medulloblastoma. The findings were published online Jan. 29 in The Lancet Oncology.

Torunn I. Yock, M.D., of Massachusetts General Hospital in Boston, and colleagues enrolled 59 patients (aged 3 to 21 years) with medulloblastoma (standard risk, 39 participants; intermediate-risk, six; and high-risk, 14) in a nonrandomized, open-label, single-center, phase 2 trial to examine the toxicity profile of proton radiotherapy.

The researchers found that the median craniospinal irradiation dose was 23.4 Gy radiobiological equivalents (GyRBE) and the median boost dose was 54.0 GyRBE. At three years, grade 3 to 4 ototoxicity in both ears was observed in four (9 percent) of 45 evaluable patients; three (7 percent) developed grade 3 to 4 ototoxicity in one ear, but one later reverted to grade 2. The cumulative incidence of grade 3 to 4 hearing loss was 12 percent (95 percent confidence interval [CI], 4 to 25 percent) at three years and 16 percent (95 percent CI, 6 to 29 percent) at five years. Progression-free survival for all patients was 83 percent (95 percent CI, 71 to 90 percent) at three years and 80 percent (95 percent CI, 67 to 88 percent) at five years (in post-hoc analyses).

Continue Reading

“Proton radiotherapy resulted in acceptable toxicity and had similar survival outcomes to those noted with conventional radiotherapy, suggesting that the use of the treatment may be an alternative to photon-based treatments,” the authors write.

One author disclosed financial ties to ProCure.

Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)